Phospholipase A2 Inhibitors
"Phospholipase A2 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit or block the activity of a PHOSPHOLIPASE A2 enzyme.
| Descriptor ID |
D064801
|
| MeSH Number(s) |
D27.505.519.389.737
|
| Concept/Terms |
Phospholipase A2 Inhibitors- Phospholipase A2 Inhibitors
- A2 Inhibitors, Phospholipase
- Inhibitors, Phospholipase A2
- Phospholipase A2 Antagonists
- A2 Antagonists, Phospholipase
- Antagonists, Phospholipase A2
|
Below are MeSH descriptors whose meaning is more general than "Phospholipase A2 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Phospholipase A2 Inhibitors".
This graph shows the total number of publications written about "Phospholipase A2 Inhibitors" by people in this website by year, and whether "Phospholipase A2 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 2 | 4 | 6 |
| 2018 | 5 | 1 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Phospholipase A2 Inhibitors" by people in Profiles.
-
The design and discovery of phospholipase A2 inhibitors for the treatment of inflammatory diseases. Expert Opin Drug Discov. 2021 11; 16(11):1287-1305.
-
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. Am Heart J. 2019 02; 208:65-73.
-
Therapeutic potential of arachidonyl trifluromethyl ketone, a cytosolic phospholipaseA2 IVA specific inhibitor, in cigarette smoke condensate-induced pathological conditions in alveolar type I & II epithelial cells. Toxicol In Vitro. 2019 Feb; 54:215-223.
-
High activity chimeric snake gamma-type phospholipase A2 inhibitor created by DNA shuffling. Toxicon. 2018 Oct; 153:32-38.
-
The inhibitory effect of saPLI?, a snake sourced PLA2 inhibitor on carrageenan-induced inflammation in mice. Toxicon. 2018 Sep 01; 151:89-95.
-
Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 06 01; 3(6):473-480.
-
Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation. Molecules. 2018 Feb 12; 23(2).
-
Snake Venom PLA2, a Promising Target for Broad-Spectrum Antivenom Drug Development. Biomed Res Int. 2017; 2017:6592820.
-
Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. J Am Heart Assoc. 2017 Oct 24; 6(10).
-
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Oct 24; 6(10).